Profile data is unavailable for this security.
About the company
NexImmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML); NEXI-002 in multiple myeloma (MM), and NEXI-003, a solid tumor product candidate for Human papillomavirus (HPV) related cancers. The Company provides Artificial Immune Modulation (AIM), which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. The Company is also developing new AIM nanoparticle constructs and modalities for clinical evaluation in oncology and autoimmune disorders.
- Revenue in USD (TTM)0.00
- Net income in USD-20.62m
- Incorporated2011
- Employees6.00
- LocationNeximmune Inc9119 Gaither RoadGAITHERSBURG 20878United StatesUSA
- Phone+1 (301) 825-9810
- Fax+1 (302) 636-5454
- Websitehttps://www.neximmune.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Seelos Therapeutics Inc | 2.01m | 4.09m | 170.02k | 8.00 | 0.0032 | -- | -- | 0.0844 | 156.15 | 156.15 | 22.91 | -135.50 | 0.2823 | -- | 6.51 | 134,266.70 | 57.34 | -180.05 | -- | -386.76 | -- | -- | 203.13 | -9,612.88 | -- | -608.33 | -- | -- | -- | -- | 48.48 | -- | -- | -- |
| Notable Labs Ltd | 313.00k | -16.74m | 194.64k | 16.00 | -- | 0.0271 | -- | 0.6219 | -2.47 | -2.47 | 0.046 | 0.7439 | 0.0176 | -- | -- | 19,562.50 | -93.89 | -52.02 | -120.26 | -62.09 | 37.70 | 60.19 | -5,346.97 | -3,636.93 | -- | -- | 0.0405 | -- | -52.89 | -11.93 | 65.13 | -- | -50.69 | -- |
| Propanc Biopharma Inc | 0.00 | -1.87m | 236.97k | 1.00 | -- | -- | -- | -- | -0.0372 | -0.0372 | 0.00 | -0.006 | 0.00 | -- | -- | -- | -1,495.00 | -4,082.63 | -- | -- | -- | -- | -- | -- | -- | -2.55 | -- | -- | -- | -- | 35.61 | -- | -- | -- |
| CNBX Pharmaceuticals Inc | 230.08k | -1.21m | 284.67k | 2.00 | -- | -- | -- | 1.24 | -0.0458 | -0.0458 | 0.0081 | -0.0789 | 0.6201 | -- | -- | 115,040.00 | -325.63 | -73.32 | -- | -99.80 | 14.96 | -- | -525.10 | -3,970.88 | -- | -1.34 | -- | -- | -- | 111.90 | 0.3497 | -- | -- | -- |
| Endonovo Therapeutics Inc | 255.72k | -4.40m | 317.46k | 0.00 | -- | -- | -- | 1.24 | -0.0652 | -0.0652 | 0.0003 | -0.072 | 0.2256 | -- | -- | -- | -388.54 | -303.26 | -- | -- | 96.21 | 74.38 | -1,722.26 | -5,956.27 | -- | -1.38 | -- | -- | 85.15 | -- | -495.02 | -- | -- | -- |
| Neximmune Inc | 0.00 | -20.62m | 338.73k | 6.00 | -- | 0.4864 | -- | -- | -18.59 | -18.59 | 0.00 | 0.66 | 0.00 | -- | -- | 0.00 | -140.56 | -115.07 | -224.94 | -165.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.25 | -- | -44.65 | -- |
| GlobeStar Therapeutics Corp | 0.00 | -1.98m | 348.88k | -- | -- | -- | -- | -- | -0.0023 | -0.0023 | 0.00 | -0.0015 | 0.00 | -- | -- | -- | -38,103.72 | -4,657.88 | -- | -- | -- | -7,790.20 | -- | -2,834,410.00 | -- | -21.00 | -- | -- | -- | -- | -31.01 | -- | -- | -- |
| Yield10 Bioscience Inc | 750.00k | -12.70m | 363.66k | 29.00 | -- | -- | -- | 0.4849 | -135.92 | -135.92 | 1.95 | -9.71 | 0.1697 | -- | -- | 25,862.07 | -287.44 | -91.26 | -- | -108.09 | -- | -- | -1,693.60 | -2,279.74 | -- | -- | -- | -- | -86.67 | -35.94 | -6.55 | -- | 1.84 | -- |
| LadRx Corp | 0.00 | -2.78m | 364.98k | 2.00 | -- | -- | -- | -- | -5.61 | -5.61 | 0.00 | -3.54 | 0.00 | -- | -- | 0.00 | -177.00 | -58.97 | -- | -78.44 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 106.96 | -- | -- | -- |
| Regenerative Medical Technology Grop Inc | 2.87m | -10.15m | 394.98k | 1.00 | -- | -- | -- | 0.1375 | -0.8144 | -0.8144 | 0.2303 | -2.07 | 0.5424 | -- | 76.15 | -- | -191.67 | -192.08 | -- | -- | 68.95 | 60.24 | -353.35 | -821.49 | 0.0257 | -0.0755 | -- | -- | 57.49 | 116.97 | -76.03 | -- | 149.35 | -- |
| Capstone Therapeutics Corp | 0.00 | -358.00k | 504.35k | 2.00 | -- | -- | -- | -- | -6.58 | -38.12 | 0.00 | -60.70 | 0.00 | -- | -- | -- | -113.46 | 141.94 | -199.60 | 173.06 | -- | -- | -- | -- | -- | -2.92 | -- | -- | -- | -- | 52.46 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Raymond James & Associates, Inc. (Invt Mgmt)as of 30 Sep 2024 | 10.80k | 0.78% |
| JPMorgan Securities LLC (Investment Management)as of 30 Sep 2024 | 0.00 | 0.00% |
| EPIQ Capital Group LLCas of 30 Sep 2024 | 0.00 | 0.00% |
| PNC Bank, NA (Investment Management)as of 30 Sep 2024 | 0.00 | 0.00% |
| RBC Dominion Securities, Inc.as of 30 Sep 2024 | 0.00 | 0.00% |
| BNP Paribas Financial Marketsas of 30 Sep 2024 | 0.00 | 0.00% |
| Bank of America, NA (Private Banking)as of 30 Sep 2024 | 0.00 | 0.00% |
| Tower Research Capital LLCas of 30 Sep 2024 | 0.00 | 0.00% |
| UBS Securities LLCas of 30 Sep 2024 | 0.00 | 0.00% |
| Sabby Management LLCas of 30 Sep 2024 | 0.00 | 0.00% |
